Kornimate/medical-research-clean huggingface dataset:
comparative research among 3 action protocol in other to approach chronic lateral epicondyle tendinopathy

Conditions: Tendinopathy

Summary: the accomplishment of a treatment with intratissue percutaneous electrolysis of additional form to the accomplishment of eccentric exercises and stretching program in patients with chronic lateral epicondyle tendinopathy is more effective than the accomplishment of an additional treatment with dry needling or eccentric exercises program realized of isolated form.

experimental study randomized with double blind, whose purpose is to compare three protocols in those who apply different protocols of physical therapy to themselves in three groups of intervention with patients with chronic lateral epicondyle tendinopathy. there take part in this study people of both sexes, with ages between 18 and 65 years, all of them present chronic lateral epicondyle tendinopathy.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * patients diagnosed of chronic lateral epicondyle tendinopathy with a minimum of 3 months of evolution. * pain when palpating the lateral epicondyle area. * positive test in at least 1 of the following 3 clinical tests: cozen, thomson or mill's * have the capacity to perform all clinical tests, understand the study process, and obtain informed consent. exclusion criteria: * previous history of direct trauma, fractures, joint instability, surgery or rheumatic alterations of the lateral epicondyle area. * full elbow extension limited. * alterations at cervical level such as: cervical radiculopathy (c4-c7), degenerative pathology in the cervical spine, exacerbated pain increase with neck movements or cervical compression. * symptoms compatible with entrapment of the posterior interosseous nerve. * nsaid intake the week before the intervention; * have received treatment with infiltration in the last year; * have received physiotherapy treatment during the last month.

Keywords: ntratissue percutaneous electrolysis dry needling eccentric exercise lateral epicondyle
effectiveness of an online religiously-integrated cognitive behavioral therapy-based intervention on death anxiety

Conditions: Death Anxiety

Summary: there has been growing awareness of the importance of death anxiety (da) in pathological anxiety. da is defined as a persistent and unreasonable fear of death and thoughts, fears, and emotions associated with the end of life. da has been suggested as a core fear that underpins the emergence and perseverance of numerous anxiety disorders. however, previous da-based treatment studies focus on the elderly, the patients, or health professionals who care for the terminally ill. therefore, there is a need to examine the effect of psychological interventions on da and current disorder symptoms in a clinical sample through randomized controlled trials. the current study aims to develop a novel religiously integrated cognitive behavioral therapy (rcbt)-based intervention on da in individuals diagnosed with an anxiety disorder and to compare the effectiveness of rcbt-based intervention with classical cbt-based intervention.

religion facilitates the pursuit of symbolic immortality by providing individuals with purpose and hope in both life and death. those who believe in an afterlife also see their world as fairer, which results in lower levels of psychiatric symptoms. previous cbt-based death anxiety interventions did not consider the assumption of an afterlife. rcbt is an approach that integrates spiritual or religious beliefs into the therapeutic process. rcbt is an approach that recognizes the importance of spirituality or religion in a client's life and aims to use these beliefs and practices positively within the context of evidence-based cbt. briefly, no intervention studies have investigated the effect of rcbt on da. this will be the first study to develop an rcbt-based intervention for da.

Eligibility criteria:
inclusion criteria: * aged 18-65 * a score of \> 26 on the turkish death anxiety scale * diagnosed with one of the anxiety disorders * believing in life after death exclusion criteria: * diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder * being in an active manic episode * possessing a mental disorder that interferes with completing measures or understanding the exercises conducted during sessions * extreme symptoms of depression (score of \> 20 on the patient health questionnaire (phq-9), and \>1 on the item assessing suicidality) * currently receiving therapy.

Keywords: death anxiety religiously integrated cognitive behavioral therapy classical cognitive behavioral therapy randomized control study
safety and biomarker study of ptc-589 in participants with parkinson's disease

Conditions: Parkinson's Disease

Summary: open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.

this is a within-subject, controlled open-label study seeking to determine if ptc-589 can alter the biochemical signature of parkinson's disease as assessed by peripheral blood biomarkers, central nervous system (cns) biomarkers, and urine biomarker analysis. in addition, data on a number of disease-relevant clinical measures will be collected.

Eligibility criteria:
inclusion criteria: * hoehn and yahr stage ≤3.0 * ambulatory with or without assistance * sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (such as, hormonal methods, including oral, subcutaneous, and intrauterine; barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study treatment. * willingness and ability to comply with study procedures * if on medications for parkinson's disease drugs, then medication regimen must be stable for 60 days prior to enrollment * abstention from use of other investigative or non-approved drugs for the duration of the trial for idiopathic participants * a diagnosis of idiopathic parkinson's disease confirmed by the presence of bradykinesia plus one or both of the following symptoms: rigidity or resting tremor; and with an abnormal datscan consistent with a dopaminergic deficit * age 40 to 75 years * within 5 years of diagnosis of parkinson's disease for genetic subtype participants * a confirmed diagnosis of parkinson's disease plus a genetic diagnosis consistent with parkinson's disease, specifically pten-induced kinase 1 (pink1), parkin, leucine-rich repeat kinase 2 (lrrk2) or other mitochondrial genetic subtype * age 21 to 75 years exclusion criteria: * allergy to ptc-589 or other components of the ptc-589 tablet formulation * use of antioxidant supplements, specifically vitamins e and c beyond the recommended daily allowance * other parkinsonian disorders * montreal cognitive assessment (moca) score of \<24 * revised hamilton rating scale for depression ≥11 * parkinsonism due to drugs or toxins * diagnosis of any other clinically significant neurologic disease that will confound the assessment of effect of study drug on disease progression * malignancy within past 2 years * pregnant or plans to become pregnant or breast feeding * history of stroke * history of brain surgery * hepatic insufficiency with liver function tests (lfts) \>3 times upper limit of normal * renal insufficiency as defined by creatinine \>1.5 times normal * end stage cardiac failure * participation within past 3 months and for duration of study in a trial of a device, drug, or other therapy for parkinson's disease

Keywords: parkinson's disease pd epi-589 epi589
the prognosis of migraine and tension-type headache in children and adolescents

Conditions: Children, Only; Headache, Migraine; Headache, Tension

Summary: children and adolescents that visited the pediatric neurology clinic at the bnai zion medical center do to migraine or tth headache between the years 2007-2010 were reevaluated. we used a structured headache questionnaire through a phone interview with the patients and their caregivers. data regarding demographics, the patients' and families' medical history, and headache history, past and current (age at onset, location, quality, frequency, duration of episodes, aura, associated symptoms and treatment) were collected.


Eligibility criteria:
inclusion criteria: * diagnosis of migraine or tth headache according to the ichd-3 criteria. * can describe the current headache status. exclusion criteria: \* secondary headaches.

Keywords: headache migraine tension type headache adolescents outcome
impact of continuing medical education (cme) insulin program

Conditions: Diabetes

Summary: the purpose of this study is to determine if a continuing medical education (cme) program can change primary care providers' use of insulin therapy - their confidence in selecting doses and engagement of patients in the decision making as to whether to initiate insulin therapy.

we will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the cme program. specifically, we will address the following questions: question 1. clinical guidelines. is insulin initiated earlier (at a lower a1c)? question 2. decision-making. does confidence in selecting a starting insulin regimen change? does confidence in selecting a starting insulin dose change? does confidence in adjusting insulin change? does confidence in discussion nutrition guidelines change? question 3. application. do more patients start using insulin? who usually selects starting dose? how is starting dose selected? how often is insulin adjusted? question 4. resources. how available are protocols for insulin use? how available is adequate time to monitor insulin therapy? how available is staff to teach insulin injections? how available is staff to help adjust insulin?

Eligibility criteria:
inclusion criteria: * primary care provider attending cme training exclusion criteria: -
comparing the hydrodynamic piezoelectric technique with osseodensification for the assessment of internal sinus iift-ing

Conditions: Bone Density, Low

Summary: successful osseointegration considered the cornerstone in implant stability which predict the highest implants success outcomes. implant stability depend on many factors like the implant design, surgical technique, and bone density. posterior maxilla considered as a challenging area in implant placement, this is due to less dense trabecular bone sur-rounded by a thin layer of cortical bone which result in suffering in implant stability. the aim of this study is to evaluate the bone density outcomes using bone densification technique and piezoelectric surgical technique in sinus lift to promote bone gain

objectives: this study was directed to compare the outcomes of internal sinus lifting between osseodensification approach and piezoelectric surgery approach on the primary stability and osseointegration of dental implant. background data: successful osseointegration considered the cornerstone in implant sta-bility which predict the highest implants success outcomes. implant stability depend on many factors like the implant design, surgical technique, and bone density. posterior maxilla considered as a challenging area in implant placement, this is due to less dense trabecular bone surrounded by a thin layer of cortical bone which result in suffering in implant stability. the aim of this study is to evaluate the bone density outcomes using bone densification technique and piezoelectric surgical technique in sinus lift to promote bone gain. materials and methods: a total of 20 patients were randomly divided into two groups: group1: patients received dental implant using osseodensification via densah bur, group2: patients received dental implant using hydrodynamic piezoelectric sinus lifting. the patients in both groups underwent bone grafting under sinus membrane. modified bleeding index and probing depth were evaluated at 3, 6 and 12months intervals. an osstell device was used to determine implant stability by recording the values of implant stability quotient (isq) immediately after implant placement and after 3 months. cbct was performed before, after 6 months and after 12 months to evaluate ridge height, bone density. marginal bone loss was evaluated after 3 months via periapical radiograph, after 6 , 12 months via cbct.

Eligibility criteria:
inclusion criteria: free of systemic disease bone height at the site of the implant is ≤ 6 mm. have good oral hygiene. - exclusion criteria: systemic diseases active periodontal disease , limited mouth-opening ability maxillary sinus disease or previous sinus surgery were also excluded smokers pregnant

Keywords: dental implant osseointegration primary implant stability , internal sinus lifting osseodensification, piezoelectric
osteoporosis treatment in post-menopausal women

Conditions: Depressive Syndrome

Summary: the study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

fracture is one of the important complications in female. osteoporosis should be treated in postmenopausal female due to high risk of fracture. recently, there have been many classes of medications developed for preventing bone loss. raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Eligibility criteria:
inclusion criteria: * postmenopausal female * osteoporosis exclusion criteria: * psychological disorders

Keywords: osteoporosis raloxifene central nervous disorders
effectiveness of vistao2 device in screening of sleep apnea/hypopnea syndrome

Conditions: Sleep Apnea Syndromes

Summary: the high prevalence (9% in men and 4% in women) of sleep apnea / hypopnea syndrome (sahs) in adults is now well documented as well as its cardiovascular repercussions. previous studies showed a conclusive link between sahs and severe cardiovascular diseases such as hypertension, myocardial infarction, heart failure and stroke.then, sahs is a public health issue in adults. in this context, early detection of such a disease is crucial if the management is tailored to the patient, the practitioner's choice of therapy moving towards continuous positive airway pressure (cpap) or mandibular advancement device. the detection is based on full nocturnal polysomnography or polygraphic recordings. polysomnography remains the gold standard but it is a time consuming and costly examination. polygraphic recording is a test that allows simplified the diagnosis of severe patients, but may not be sufficient for mild form of sahs. thus, the sahs is a pathology under-diagnosed and under-treated. the validation of a technique for identifying patients most at risk to either limit the number of polysomnographic examination is requested.

in this perspective, the development of a product screening sleep related breathing disorders for physicians, cardiologists, internists (not specialized sleep experts) would fill this need. it allows for a reliable first screening for their patients in parallel with a routine cardiological examination. imposing a minimal human and material, the ecg holter recorder "vistao2" (novacor, rueil-malmaison, france) is a device designed to meet these requirements. this device fits into the daily management of patients with cardiac arrhythmias or sinus/atrioventricular conduction disorders, and of patients suffering myocardial infarction (arrhythmic risk stratification, detection of silent myocardial ischemia). analysis of heart rate variability (hrv) has already shown interest in screening sahs. we therefore wish to evaluate the performance of the analysis of data from the screening tool vistao2 face what the gold standard synchronized polysomnography.

Eligibility criteria:
inclusion criteria: * sleep apnea hypopnea syndrome suspicion * written consent exclusion criteria: * pacemaker * diabetes * atrial fibrillation * electrode allergy

Keywords: sleep apnea syndromes polysomnography holter ecg thoracic impedance heart rate variability
follow up of stroke patients by neurologists and general practitioners

Conditions: Stroke

Summary: from the region around brussels there are currently few data on how the post-stroke process take place and how satisfied the care providers are with it. for this reason, this survey is set up with the aim of examining four pillars: the epidemiology of stroke, communication between neurologists and gps and satisfaction with it, secondary prevention of cardiovascular disease and control/treatment of the most common sequelae after stroke. in the latter two, the emphasis is on detection and treatment, and explicitly on whose task this is (neurologist versus gp), with the aim of verifying the mutual consensus on treatment and the subsequent detection of treatment shortcomings. this study will mainly consist of interviewing general practitioners and neurologists in the periphery of brussels. this will be done by means of partly structured questionnaires, that will be send out to the medical professionals by contact with the central umbrella organisations of neurology in the hospitals and contact with the various general practitioners' practices (directly or through the multidisciplinary meetings per region). the questionnaires will be made up in google forms, as this programme allows efficient data processing, is eas-ily understandable for every participant and as no individual patient data will be processed.


Eligibility criteria:
inclusion criteria: * neurologist and/or general practitioner exclusion criteria: * not actively treating stroke patients
association between levels of d-dimer, fibrinogen and pai-1 in elderly patients with infection and occurrence of cardio- and cerebro-vascular disease after discharge

Conditions: Infection; Acute Coronary Syndrome; Cerebrovascular Disease

Summary: the association between the levels of d-dimer, fibrinogen and pai-1 in plasma of elderly patients admitted to internal medicine departments because of infection and the occurrence of cardio- and cerebro-vascular disease after discharge


Eligibility criteria:
inclusion criteria: * acute infection exclusion criteria: * anticoagulant therapy

Keywords: cerebro vascular event
adapted physical activity program after sleeve gastrectomy

Conditions: Obesity

Summary: this study compares the ratio of lean mass losses over total body mass losses between patients undergoing sleeve gastrectomy followed by physical activity training versus patients undergoing sleeve gastrectomy only

this study will assess prospectively and objectively the potential benefits of a personalized and specific rehabilitation program designed for patients who undergone sleeve gastrectomy. this strategy will help to reduce fat mass and to limit lean mass loss, in order to prevent in the short term the overweight recurrence. also,the improvement of physical and metabolic status is expected.

Eligibility criteria:
inclusion criteria: * bmi \>40 kg/m² or bmi\>35kg/m² with comorbidities qualifying for bariatric surgery * stable obesity or obesity evolving for more than 5 years * patient cleared by the surgeon for sleeve gastrectomy one month before recruitment * absence of contraindication for a sub-maximal stress test * performance of a polysomnography before surgery * signed informed consent * patient benefiting from health care coverage exclusion criteria: * absence of preliminary and regular medical check-ups mandatory before sleeve gastrectomy * anticipated difficulty for patient follow-up * mental diseases (psychosis, depression, suicidal behavior or history) * eating disorders * lack of informed consent or cooperation * unsufficient patient commitment * patient under judiciary protection * patient not able to comply with any or all the research procedures over time including physical activity * patient excluded from the french database of volunteers for clinical trials

Keywords: obesity sleeve gastrectomy personalized physical activity program body composition fat mass lean mass
cetuximab as therapy for recurrent non-small cell lung cancer patients who have received prior therapy

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this research study is to find out how well cetuximab works in treating nsclc in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (tki). cetuximab is a protein that is designed to block a substance in cancer cells called "epidermal growth factor receptor" or egfr. egfr helps cancer cells grow.

* participants on this study will receive cetuximab by infusion intravenously once per week and may continue to receive weekly cetuximab infusions until their disease progresses or they experience unacceptable side effects. * the following will be performed every 4 weeks while they are receiving study treatments: physical examination; performance status; and blood work. a ct scan of the chest and upper abdomen will be performed every 8 weeks.

Eligibility criteria:
inclusion criteria: * pathologically confirmed stage iiib or iv recurrent or progressive nsclc * patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the egfr pathway * measurable disease, as defined by recist criteria * patients must have a suitable frozen or paraffin-embedded tissue sample available for egfr mutational analysis. prior egfr mutational analyses are allowable * patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable * ecog performance status 0-2 * 18 years of age or older * negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential * bone marrow function, renal function, hepatic function as outlined in protocol exclusion criteria: * women who are pregnant of breastfeeding * active concurrent malignancy * major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab * significant history of uncontrolled cardiac disease * uncontrolled seizure disorder, or active neurological disease * prior severe infusion reactions to a monoclonal antibody * prior chemotherapy regimen within 21 days prior to study entry * any egfr tyrosine kinase inhibitor within 14 days of study entry * radiation therapy within 14 days prior to the first infusion of cetuximab * acute hepatitis or known hiv * active or uncontrolled infection * any concurrent chemotherapy or any other investigational agent(s)

Keywords: cetuximab tyrosine kinase inhibitor